Tibolone inhibits bone resorption without secondary positive effects on cartilage degradation

BMC Musculoskeletal Disorders

Volumn 9, Issue , 2008, Pages

  Karsdal, M A ^a   Byrjalsen, I ^a   Leeming, D J ^a   Christiansen, C ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TIBOLONE; ANDROGEN RECEPTOR; COLLAGEN TYPE 11; COLLAGEN TYPE 12; ESTROGEN RECEPTOR; PREGNANE DERIVATIVE; PROGESTERONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; AGED; ARTICLE; BONE TURNOVER; CARTILAGE DEGENERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; OSTEOLYSIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; URINALYSIS; ARTICULAR CARTILAGE; BONE; DOSE RESPONSE; DRUG EFFECT; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; URINE;

AGED; BONE AND BONES; BONE RESORPTION; CARTILAGE, ARTICULAR; COLLAGEN TYPE XI; COLLAGEN TYPE XII; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; NORPREGNENES; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 57749200910     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-9-153     Document Type: Article

References (60)

1. Prospects for disease modification in osteoarthritis. SB Abramson M Attur Y Yazici, Nat Clin Pract Rheumatol 2006 2 304 312 10.1038/ncprheum0193 16932709
2. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. LD Carbone MC Nevitt K Wildy KD Barrow F Harris D Felson, Arthritis Rheum 2004 50 3516 3525 10.1002/art.20627 15529367
3. Osteoarthritis: is it a disease of cartilage or of bone? DT Felson T Neogi, Arthritis Rheum 2004 50 341 344 10.1002/art.20051 14872473
4. The effects of estrogen on osteoarthritis. DT Felson MC Nevitt, Curr Opin Rheumatol 1998 10 269 272 10.1097/00002281-199805000-00019 9608332
5. Estrogen replacement therapy and the development of osteoarthritis. SA Oliveria DT Felson RA Klein JI Reed AM Walker, Epidemiology 1996 7 415 419 10.1097/00001648-199607000-00013 8793369
6. Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. U Mouritzen S Christgau HJ Lehmann LB Tanko C Christiansen, Ann Rheum Dis 2003 62 332 336 12634232 10.1136/ard.62.4.332
7. The Effect of Oral Calcitonin on Cartilage Turnover and Surface Erosion in the Ovariectomized Rat Model. BC Sondergaard S Ostergaard C Christiansen MA Karsdal, Arthritis Rheum 2007 56 8 2674 2678 10.1002/art.22797 17665432
8. Estradiol and its metabolites and their association with knee osteoarthritis. MR Sowers D McConnell M Jannausch AG Buyuktur M Hochberg DA Jamadar, Arthritis Rheum 2006 54 2481 2487 10.1002/art.22005 16871545
9. The incidence and natural history of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. DT Felson Y Zhang MT Hannan A Naimark BN Weissman P Aliabadi, Arthritis Rheum 1995 38 1500 1505 10.1002/art.1780381017 7575700
10. Effects of long-term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys. KD Ham RF Loeser BR Lindgren CS Carlson, Arthritis Rheum 2002 46 1956 1964 10.1002/art.10406 12124881
11. Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. S Oestergaard BC Sondergaard P Hoegh-Andersen K Henriksen P Qvist C Christiansen, Arthritis Rheum 2006 54 2441 2451 10.1002/art.22009 16871544
12. Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). S Christgau LB Tanko PA Cloos U Mouritzen C Christiansen JM Delaisse, Menopause 2004 11 508 518 10.1097/01.WCB.0000121484.18437.98 15356403
13. Treatment of climacteric complaints with Org OD 14: a comparative study with oestradiol valerate and placebo. N Crona G Samsioe UB Lindberg G Silfverstolpe, Maturitas 1988 9 303 308 10.1016/0378-5122(88)90095-3 3288845
14. Placebo-controlled cross-over study of effects of Org OD 14 in menopausal women. PM Kicovic J Cortes-Prieto M Luisi S Milojevic F Franchi, Reproduccion 1982 6 81 91 6754512
15. Multicentre study of effects of Org OD 14 on endometrium, vaginal cytology and cervical mucus in post-menopausal and oophorectomized women. R Punnonen P Liukko J Cortes-Prieto F Eydam S Milojevic R Trevoux, Maturitas 1984 5 281 286 10.1016/0378-5122(84)90023-9 6738375
16. Org OD 14 and the endometrium. AR Genazzani LJ Benedek-Jaszmann DM Hart L Andolsek PM Kicovic L Tax, Maturitas 1991 13 243 251 10.1016/0378-5122(91) 90199-Z 1943832
17. Receptor profiling and endocrine interactions of tibolone. ME de Gooyer GH Deckers WG Schoonen HA Verheul HJ Kloosterboer, Steroids 2003 68 21 30 10.1016/S0039-128X(02)00112-5 12475720
18. A primate model of human postmenopausal hot flushes. J Jelinek A Kappen E Schonbaum P Lomax, J Clin Endocrinol Metab 1984 59 1224 1228 6490799
19. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day. MB Landgren FA Helmond S Engelen, Maturitas 2005 50 222 230 10.1016/j.maturitas.2004.06.001 15734603
20. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. P Geusens J Dequeker J Gielen LP Schot, Maturitas 1991 13 155 162 10.1016/0378-5122(91)90099-C 1921738
21. Tibolone: prevention of bone loss in late postmenopausal women. NH Bjarnason K Bjarnason J Haarbo C Rosenquist C Christiansen, J Clin Endocrinol Metab 1996 81 2419 2422 10.1210/jc.81.7.2419 8675554
22. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? S Schaller K Henriksen P Hoegh-Andersen BC Sondergaard EU Sumer LB Tanko, Assay Drug Dev Technol 2005 3 553 580 10.1089/adt.2005.3.553 16305312
23. The chloride channel inhibitor n53736 prevents bone resorption in ovariectomized rats without changing bone formation. S Schaller K Henriksen C Sveigaard AM Heegaard N Helix M Stahlhut, J Bone Miner Res 2004 19 1144 1153 10.1359/JBMR.040302 15176998
24. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. P Ravn D Hosking D Thompson G Cizza RD Wasnich M McClung, J Clin Endocrinol Metab 1999 84 2363 2368 10.1210/jc.84.7.2363 10404804
25. Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. BC Sondergaard K Henriksen H Wulf S Oestergaard U Schurigt R Brauer, Osteoarthritis Cartilage 2006 14 738 748 10.1016/j.joca.2006.01.016 16563811
26. Evaluation of cartilage damage by measuring collagen degradation products in joint extracts in a traumatic model of osteoarthritis. Rh Nielsen R Stoop DJ Leeming M Stolina P Qvist C Christiansen, Biomarkers 2008 13 79 87 10.1080/13547500701615108 17852072
27. A new marker for osteoarthritis: cross-sectional and longitudinal approach. M Reijman JM Hazes SM Bierma-Zeinstra BW Koes S Christgau C Christiansen, Arthritis Rheum 2004 50 2471 2478 10.1002/art.20332 15334460
28. Should subchondral bone turnover be targeted when treating osteoarthritis? MA Karsdal DJ Leeming EB Dam K Henriksen P Alexandersen P Pastoureau, Osteoarthritis Cartilage 2008 16 6 638 646 10.1016/j.joca.2008.01. 014 18362080
29. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. T Hayami M Pickarski GA Wesolowski J McLane A Bone J Destefano, Arthritis Rheum 2004 50 1193 1206 10.1002/art.20124 15077302
30. Bone, not cartilage, should be the major focus in osteoarthritis. JP Mansell C Collins AJ Bailey, Nat Clin Pract Rheumatol 2007 3 306 307 10.1038/ncprheum0505 17538562
31. Abnormal cancellous bone collagen metabolism in osteoarthritis. JP Mansell AJ Bailey, J Clin Invest 1998 101 1596 1603 9541489 10.1172/JCI867
32. Do subchondral bone changes exacerbate or precede articular cartilage destruction in osteoarthritis of the elderly? AJ Bailey JP Mansell, Gerontology 1997 43 296 304 9309420
33. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. CO Bingham III JC Buckland-Wright P Garnero SB Cohen M Dougados S Adami, Arthritis Rheum 2006 54 3494 3507 10.1002/art.22160 17075851
34. Treatment with risedronate reduced urinary CTX-II, a specificbiochemical marker of cartilage type II collagen degradation in a 24 month study of knee OA. P Garnero C Bingham W Aronstein S Cohen P Conaghan G Cline, ACR Abstract book 2005 S656
35. The effect on cartilage of different forms of application of postmenopausal estrogen therapy: comparison of oral and transdermal therapy. P Ravn L Warming S Christgau C Christiansen, Bone 2004 35 1216 1221 10.1016/j.bone.2004.07.017 15542048
36. Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women. P Alexandersen MA Karsdal P Qvist JY Reginster C Christiansen, Bone 2007 40 218 222 10.1016/j.bone.2006.07.028 17010685
37. Effects of estrogen replacement therapy on bone turnover in subchondral bone and epiphyseal metaphyseal cancellous bone of ovariectomized cynomolgus monkeys. KD Ham CS Carlson, J Bone Miner Res 2004 19 823 829 10.1359/JBMR.040309 15068506
38. Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. T Hayami M Pickarski Y Zhuo GA Wesolowski GA Rodan LT Duong, Bone 2005 16185945
39. Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. P Garnero C Peterfy S Zaim M Schoenharting, Arthritis Rheum 2005 52 2822 2829 10.1002/art.21366 16145678
40. Evidence of altered bone turnover, vitamin D and calcium regulation with knee osteoarthritis in female twins. DJ Hunter D Hart H Snieder P Bettica R Swaminathan TD Spector, Rheumatology (Oxford) 2003 42 1311 1316 10.1093/rheumatology/keg373 12867590
41. The role of bone metabolism in osteoarthritis. DJ Hunter TD Spector, Curr Rheumatol Rep 2003 5 15 19 10.1007/s11926-003-0078-5 12590880
42. Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. P Dieppe J Cushnaghan P Young J Kirwan, Ann Rheum Dis 1993 52 557 563 8215615 10.1136/ard.52.8.557
43. Osteoarthritis: epidemiology. N Arden MC Nevitt, Best Pract Res Clin Rheumatol 2006 20 3 25 10.1016/j.berh.2005.09.007 16483904
44. Osteoporosis increases the severity of cartilage damage in an experimental model of osteoarthritis in rabbits. E Calvo S Castaneda R Largo ME Fernandez-Valle F Rodriguez-Salvanes G Herrero-Beaumont, Osteoarthritis Cartilage 2006 16861013
45. Osteoarthritis severity is sex dependent in a surgical mouse model. HL Ma TJ Blanchet D Peluso B Hopkins EA Morris SS Glasson, Osteoarthritis Cartilage 2007 15 695 700 10.1016/j.joca.2006.11.005 17207643
46. Ovariectomized rats as a model of postmenopausal osteoarthritis: validation and application. P Hoegh-Andersen LB Tanko TL Andersen CV Lundberg JA Mo AM Heegaard, Arthritis Res Ther 2004 6 R169 R180 15059281 10.1186/ar1152
47. Estrogen directly attenuates human osteoclastogenesis, but has no effect on resorption by mature osteoclasts. MG Sorensen K Henriksen MH Dziegiel LB Tanko MA Karsdal, DNA Cell Biol 2006 25 475 483 10.1089/dna.2006.25.475 16907645
48. Estrogens, cartilage, and osteoarthritis. P Richette M Corvol T Bardin, Joint Bone Spine 2003 70 257 262 10.1016/S1297-319X(03)00067-8 12951307
49. Estrogen receptors in cultured rabbit articular chondrocytes: influence of age. N Dayani MT Corvol P Robel B Eychenne B Moncharmont L Tsagris, J Steroid Biochem 1988 31 351 356 10.1016/0022-4731(88)90361-5 3419165
50. Immunohistochemical detection of estrogen receptor alpha in articular chondrocytes from cows, pigs and humans: in situ and in vitro results. H Claassen J Hassenpflug M Schunke W Sierralta H Thole B Kurz, Ann Anat 2001 183 223 227 11396791
51. Expression of genes for estrogen receptors alpha and beta in human articular chondrocytes. T Ushiyama H Ueyama K Inoue I Ohkubo S Hukuda, Osteoarthritis Cartilage 1999 7 560 566 10.1053/joca.1999.0260 10558854
52. Functional estrogen receptors in adult articular cartilage: estrogen replacement therapy increases chondrocyte synthesis of proteoglycans and insulin-like growth factor binding protein 2. RS Richmond CS Carlson TC Register G Shanker RF Loeser, Arthritis Rheum 2000 43 2081 2090 10.1002/1529- 0131(200009)43:9<2081::AID-ANR20>3.0.CO;2-I 11014360
53. Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate. C Christiansen LB Tanko L Warming A Moelgaard S Christgau P Qvist, Osteoporos Int 2003 14 609 613 10.1007/s00198-003-1409-0 12830369
54. Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. HJ Lehmann U Mouritzen S Christgau PA Cloos C Christiansen, Ann Rheum Dis 2002 61 6 530 533 12006327 10.1136/ard.61.6.530
55. Effect of hormone therapy on risk of hip and knee joint replacement in the Women's Health Initiative. DJ Cirillo RB Wallace L Wu RA Yood, Arthritis Rheum 2006 54 3194 3204 10.1002/art.22138 17009251
56. The utility of measuring C-terminal telopeptides of collagen type II (CTX-II) in serum and synovial fluid samples for estimation of articular cartilage status in experimental models of destructive joint diseases. S Oestergaard L Chouinard N Doyle MA Karsdal SY Smith P Qvist, Osteoarthritis Cartilage 2006 14 670 679 10.1016/j.joca.2006.01.004 16500121
57. Characterization of metalloprotease cleavage products of human articular cartilage. EY Zhen IJ Brittain DA Laska PG Mitchell EU Sumer MA Karsdal, Arthritis Rheum 2008 58 2420 2431 10.1002/art.23654 18668564
58. Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study. I Meulenbelt M Kloppenburg HM Kroon JJ Houwing-Duistermaat P Garnero MP Hellio Le Graverand, Ann Rheum Dis 2006 65 360 365 10.1136/ard.2005.040642 16079167
59. Clusters of biochemical markers are associated with radiographic subtypes of osteoarthritis (OA) in subject with familial OA at multiple sites. The GARP study. I Meulenbelt M Kloppenburg HM Kroon JJ Houwing-Duistermaat P Garnero MP Hellio-Le Graverand, Osteoarthritis Cartilage 2007 15 379 385 10.1016/j.joca.2006.09.007 17052923
60. Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. EB Dam I Byrjalsen MA Karsdal P Qvist C Christiansen, Osteoarthritis Cartilage 2008